Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
CERE was delisted on the 31st of July, 2024.
114 hedge funds and large institutions have $3.78B invested in Cerevel Therapeutics Holdings, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 59 increasing their positions, 19 reducing their positions, and 13 closing their positions.
211% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 19
46% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 13
29% more call options, than puts
Call options by funds: $16M | Put options by funds: $12.4M
16% more capital invested
Capital invested by funds: $3.27B → $3.78B (+$517M)
6% more funds holding
Funds holding: 108 → 114 (+6)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$82M |
| 2 |
PA
Perceptive Advisors
New York
|
+$42.4M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$31.9M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$26.3M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$25.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$45.5M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$43.5M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$11.9M |
| 4 |
ABG
Ally Bridge Group
New York
|
-$4.5M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$2.06M |
CERE Hedge Fund Activity: Q3 2022 in Review
114 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) for Q3 2022, worth a combined $3.78B — up 16% from $3.27B a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new CERE positions and 13 closed out — a net gain of 6 holders — while 59 added to existing stakes and 19 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $82M. The largest seller was T. Rowe Price Associates, cutting an estimated $45.5M.
- 114 institutional investors held Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) as of Q3 2022, up from 108 in Q2 2022.
- Funds reported $3.78B of Cerevel Therapeutics Holdings, Inc. Common Stock stock for Q3 2022, up 16% quarter-over-quarter.
- 19 funds opened new Cerevel Therapeutics Holdings, Inc. Common Stock positions in Q3 2022 and 13 closed out, a net change of +6 holders.
- The largest Cerevel Therapeutics Holdings, Inc. Common Stock buyer in Q3 2022 was Janus Henderson Group, an estimated $82M added.
- The largest Cerevel Therapeutics Holdings, Inc. Common Stock seller in Q3 2022 was T. Rowe Price Associates, an estimated $45.5M sold.
Based on aggregated 13F filings for Q3 2022.